Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17811675 | 0.89 | CYP3A4 (0.33) | CYP3A4CYP2C9 | |
| SCHEMBL16437152 | 0.84 | CYP3A4 (0.32) | CYP3A4CYP2C9 | |
| SCHEMBL17811667 | 0.84 | CYP3A4 (0.32) | RXRAGRIN1GRIN2BCYP3A4CYP2C9 | |
| SCHEMBL17811668 | 0.84 | HTR1A (0.32) | CYP3A4CYP2C9HTR1ADRD2HTR2A | |
| SCHEMBL16437544 | 0.84 | SSTR4 (0.34) | CYP3A4CYP2C9HTR1A | |
| SCHEMBL17811657 | 0.83 | RXRA (0.32) | RXRAGRIN1GRIN2B | |
| SCHEMBL17796906 | 0.83 | PPARG (0.35) | RXRAGRIN1GRIN2B | |
| SCHEMBL17811656 | 0.83 | PIK3CA (0.30) | — | |
| SCHEMBL17804255 | 0.82 | CYP3A4 (0.32) | CYP3A4CYP2C9 | |
| SCHEMBL16437158 | 0.82 | CYP3A4 (0.31) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9521848-B2 | Tetrazolinone compound and use therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | CYP51A1, CYP4F11, CYP1B1 | RXRA 868/4885GRIN1 810/4885GRIN2B 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.